This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2026 Remove Patient Care Remove Vaccines Related Topics
HIV Treatment and Prevention Agents Medication Delivery Pharmaceutical Companies Labelling FDA Pharmaceutical Companies More Related Topics >
article thumbnail

Meet the 2023 Social Impact Category Winner: Takeda SA

ISPE

SEPTEMBER 29, 2023

For more than 240 years, Takeda has focused on delivering transformative treatments in the therapeutic areas of gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Takeda has reduced CO2 emission by 861 tons.

Pharmaceutical Companies 52
Pharmaceutical Companies Pharmaceutical Companies Labelling Patient Care 52
article thumbnail

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The prescription medicine market has recovered from the wild swings of the early pandemic with renewed growth.

HIV Treatment and Prevention Agents 59
HIV Treatment and Prevention Agents Vaccines Pharmaceutical Companies Pharmaceutical Companies 59
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 18,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024